SEC Form 4 · accession 0001562180-16-001278
BIO-TECHNE Corp · TECH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin S Gould
Officer — SVP Clinical Controls
Period of report
Jan 4, 2016
Accepted (ET)
Jan 6, 2016 · 5:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000842023
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 2,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy)F2 | $88.23 | Jan 4, 2016 | A | 10,000 | A | — | Jan 4, 2023 | Common Stock | 10,000 | 10,000 | D |
| Stock Options (Right to buy)F3 | $97.23 | holding | — | — | — | — | Jul 9, 2022 | Common Stock | 50,000 | 50,000 | D |
| Stock Options (Right to buy)F4 | $97.23 | holding | — | — | — | — | Jul 9, 2022 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1Represents 2,500 restricted stock units that vest in increments of 833 shares on 07/09/16 and 07/09/17 and 834 shares on 07/09/18.
- F2Vests as to 2,500 shares on each of 01/04/2017, 01/04/2018, 01/04/2019 and 01/04/2020.
- F350,000 common stock options vest if certain performance goals are achieved for the 12 months ending 05/31/2018.
- F4Vests as to 3,750 shares on each of 07/09/16, 07/09/17, 07/09/18 and 07/09/19.